Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sigvotatug vedotin + pembrolizumab versus pembrolizumab first-line for PD-L1-high advanced NSCLC
jRCT2051240299Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Sigvotatug Vedotin with Pembrolizumab with Pembrolizumab Monotherapy (2 arms). Primary endpoints: Overall survival and Progression-free survival by blinded independent central review. Started Jul 2025; status: recruiting.
02
Drugs
sigvotatug vedotinpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240299.